ONC — Oncolytics Biotech Balance Sheet
0.000.00%
Last trade - 00:00- CA$114.61m
- CA$80.12m
Annual balance sheet for Oncolytics Biotech, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 14.1 | 31.2 | 41.3 | 32.1 | 34.9 |
| Net Total Receivables | 2.07 | 0.09 | 0.866 | 0.521 | 0.015 |
| Prepaid Expenses | |||||
| Total Current Assets | 18.9 | 33.7 | 44.9 | 35.7 | 38.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.727 | 0.609 | 0.976 | 0.652 | 0.647 |
| Other Long Term Assets | |||||
| Total Assets | 19.7 | 34.3 | 45.9 | 37.3 | 38.8 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 12.9 | 2.71 | 2.69 | 3.94 | 4.24 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 19.8 | 9.59 | 9.78 | 10.8 | 11.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -0.108 | 24.8 | 36.1 | 26.5 | 27.6 |
| Total Liabilities & Shareholders' Equity | 19.7 | 34.3 | 45.9 | 37.3 | 38.8 |
| Total Common Shares Outstanding |